Lori Goldstein, MD, FASCO
- Request Appointment
- Clinical Locations
- About
- Education and Training
- Patient Stories
- Research Profile
- Publications
- Ratings
Clinical Locations
Primary Location
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Director, The Naomi and Phil Lippincott Breast Evaluation Center
Deputy Associate Director, Clinical Research
Professor, Department of Hematology/Oncology
NCCN, Breast Cancer Panel Member
Specialties
Treatment Focus
- Systemic chemotherapy, hormonal therapy and biologic therapy for early and advanced stage breast cancer
- Clinical and translational trials in breast cancer
Research Program
Key Awards
Medical Oncology
Treatment Philosophy
Educational Background
- Fellow, Oncology, Division of Cancer Treatment and Division of Cancer Biology and Diagnosis, National Cancer Institute, Washington, DC
- Resident, Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA
- MD, State University of New York Upstate College of Medicine, Syracuse, NY, 1982
Certifications
- American Board of Internal Medicine
- Internal Medicine
- Medical Oncology
Memberships
- National Comprehensive Cancer Network (NCCN)
- Breast Cancer Panel
- Program Director, Breast Cancer Symposium, Fox Chase Cancer Center
- Course Director, Fox Chase Cancer Center Highlights of SABCS CME Program
- American Association for the Advancement of Science
- American Association of Cancer Research
- American Society of Clinical Oncology
- National Accreditation Program for Breast Cancer Centers
- Women in Cancer Research
Honors & Awards
- Best Doctors in America® , 2013-15, 2019-2020, Medical Oncology and Hematology
- Philadelphia magazine Top Doctors, 2009-19
- Forbes Magazine list of 27 Top Breast Cancer Oncologists, 2017
- America’s Top Doctors®, 2012-2017
- Susan G. Komen "Light of Life Award,” 2014
Karen Lucas
Karen Lucas
For more than 20 years, Karen Lucas has been diligent about getting annual mammograms, as well as yearly visits to her OB/GYN. At the age of 65, during a routine mammogram in August 2012, the test showed calcification in both breasts.
Patti Rose
Patti Rose
At 36, Patti Rose, a wife and mother to seven children, was shocked to learn she had a rare form of breast cancer. Because her husband works in construction and had done several projects for Fox Chase Cancer Center, they knew right away Fox Chase was the right place for Patti's treatment. At Fox Chase, Patti underwent chemotherapy and radiation therapy, followed by a lumpectomy and additional surgery. The experience was extremely difficult, but Patti credits the staff at Fox Chase for giving her a positive outlook and helping her get through it. Today, she is cancer free and could not be more pleased with the treatment she received. "Fox Chase helped me to be positive. If I didn’t have that connection with doctors and nurses and even the security guard that I would talk to every time I was there, I think I would have felt more afraid," she said. "Knowing all those people were praying for me, thinking of me, and trying to get me through it made me feel like I could overcome it."
Laura Marblestone
Laura Marblestone
Because Laura Marblestone's mother lost her fight with breast cancer at the age of 43, Laura regularly performed breast self-exams. In 1991, she was diagnosed with encapsulated metastatic carcinoma, and a friend recommended she seek treatment at Fox Chase Cancer Center. After a mestectomy and a round of chemotherapy, Laura was considered cancer free, but in 2006, she found a lump in her right breast; the cancer had returned. She underwent a second mastectomy, chemotherapy, and breast reconstructive surgery. "Even though it took me three months to recover, I would do it again in a heartbeat," she said. "The doctors at Fox Chase were thorough--they didn't leave a stone unturned."
Shari Lynn
Shari Lynn
In 2002, Shari Lynn's husband, Mark, accepted a new job in another state. Together, Shari and Mark made the decision to move their family from New York to Pennsylvania. Shari was like many other moms in her situation. In preparing for the move, she scheduled routine doctor appointments on Long Island so they would not feel pressured to find new physicians right away.
Marlene Haney
Marlene Haney
When Marlene Haney turned 60 in 2013 she decided the best gift she could give herself was a physical she had been putting off. Self–employed and without supplemental health insurance, she says she had not be in a position to see a doctor for over a decade. When her right breast became tender, she realized a trip to the doctor was necessary.
Pages
Research Program
Research Interests
- Translational studies in breast cancer
- Development of novel therapeutic strategies in breast cancer
- Molecular targeting of breast cancer
Selected Publications
Blackwell KL, Zaman K, Qin S, Tkaczuk KHR, Campone M, Hunt D, Bryce R, Goldstein LJ, Study G. Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study. Clinical breast cancer, 19(2):97-104.e4, 2019. PubMed
Goldstein, LJ, Gray, R, Badve, S, Childs, BH, Yoshizawa, C, Rosley, S, Shak, S, Baehner, FL, Ravdin PM, Davidson, NE, Sledge, GW, Perez, E, Shulman, LN, Martino, S, Sparano, JA: Prognostic Utility of the 21-Gene Assay in Hormone Receptor Positive Operable Breast Cancer with Classical Prognostic Factors and an Integrator of Classical Clinicopathologic and Treatment Information. JCO, Vol. 26, No. 25, Pg. 4063, September 2, 2008. PubMed
Goldstein, L.J., O’Neill, A., Sparano, J.A., Perez, E.A., Shulman, L.N., Martino, S.,Davidson, N.: Concurrent doxorubicin plus doxetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0-3 positive axillary nodes: results of North American Breast Cancer Intergroup Trial E2197. JCO, Vol. 26, No. 25, Pg. 4092, September 2, 2008. PubMed
Finn, RS, Bengala, C, Strauss, LC, Fairchild, J, Sy, O, Ibrahim, N, Rouche, H, Sparano, J, Goldstein, LJ.: Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study. Clin Cancer Res. 2011 Nov 1;17(21):6905-13.
Tevaarwerk AJ, Gray R, Schneider BP, Smith ML, Wagner LI, Fetting J, Davidson N, Goldstein LJ, Miller KD, Sparano JA. Survival in Metastatic Recurrent Breast Cancer after Adjuvant Chemotherapy: Little Evidence for Improvement Over the Past Three Decades. Cancer. 2013 Mar;119(6):1140-8. PMCID: 3593800
Goldstein, LJ, Tosello-Oliveria, C, Heinrich B, Stemmer SM, Mala C, Kastner S, Bevan P Richters L, Schmalfeldt B, Harbeck N. A Randomized double-blind phase II study of the combination of oral WX-671 plus capecitabine vs capecitabine monotherapy in first-line HER2-negative metastatic breast cancer (MBC). ASCO 2013 Oral presentation, J. Clin Oncol 31, suppl; Abstract 508.
Goldstein LJ, Gurtler J, Del Prete SA, Tjulandin S, Semiglazov VF, Bayever E, Michiels B. Trabectedin as a Single-Agent Treatment of Advanced Breast Cancer After Anthracycline and Taxane Treatment: A Multicenter, Randomized, Phase II Study Comparing 2 Administration Regimens. Clinical Breast Cancer, 14(6):396-404, 2014.
Freedman GM, Fowble BL, Li T, Hwang ES, Schechter N, Devarajan K, Anderson PR, Sigurdson ER, Goldstein LJ, Bleicher RJ.: Risk of Positive Nonsentinel Nodes in Women with 1-2 Positive Sentinel Nodes Related to Age and Molecular Subtype Approximated by Receptor Status. Breast J Vol. 20(4) 358-363, July 2014. PubMed
Adams S, Gray RJ, Demaria S, Goldstein LJ, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, Badve SS.: Prognostic Value of Tumor-Infiltrating Lymphocytes (TILs) in Triple Negative Breast Cancers (TNBC) from two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014 Sept 20; 32(27):2959-67. PMID: 25513417.
Silverman, D, Ruth, KJ, Sigurdson, E, Egleston, BL, Goldstein, LJ, Boraas, M, Bleicher R.: Skin Involvement and Breast Cancer: Are T4b Lesions of All Sizes Created Equal? Journal of the American College of Surgeons. Vol 219(3) 534-544 September 2014. PMCID: 4143438.
Matro J, Walia R, Tumelty K, Morrison T, Goldstein LJ.: Bilateral Hypoglossal Nerve Palsy Due to Breast Cancer Skull Base Metastases. AJHO Vol 10(5) 14-16, Nov. 2014.
Additional Publications
Clinical Locations
Primary Location
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Director, The Naomi and Phil Lippincott Breast Evaluation Center
Deputy Associate Director, Clinical Research
Professor, Department of Hematology/Oncology
NCCN, Breast Cancer Panel Member
Specialties
Treatment Focus
- Systemic chemotherapy, hormonal therapy and biologic therapy for early and advanced stage breast cancer
- Clinical and translational trials in breast cancer
Research Program
Key Awards
Medical Oncology
Treatment Philosophy
Education
Educational Background
- Fellow, Oncology, Division of Cancer Treatment and Division of Cancer Biology and Diagnosis, National Cancer Institute, Washington, DC
- Resident, Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA
- MD, State University of New York Upstate College of Medicine, Syracuse, NY, 1982
Certifications
- American Board of Internal Medicine
- Internal Medicine
- Medical Oncology
Memberships
- National Comprehensive Cancer Network (NCCN)
- Breast Cancer Panel
- Program Director, Breast Cancer Symposium, Fox Chase Cancer Center
- Course Director, Fox Chase Cancer Center Highlights of SABCS CME Program
- American Association for the Advancement of Science
- American Association of Cancer Research
- American Society of Clinical Oncology
- National Accreditation Program for Breast Cancer Centers
- Women in Cancer Research
Honors & Awards
- Best Doctors in America® , 2013-15, 2019-2020, Medical Oncology and Hematology
- Philadelphia magazine Top Doctors, 2009-19
- Forbes Magazine list of 27 Top Breast Cancer Oncologists, 2017
- America’s Top Doctors®, 2012-2017
- Susan G. Komen "Light of Life Award,” 2014
Research Profile
Research Interests
- Translational studies in breast cancer
- Development of novel therapeutic strategies in breast cancer
- Molecular targeting of breast cancer
Publications
Selected Publications
Blackwell KL, Zaman K, Qin S, Tkaczuk KHR, Campone M, Hunt D, Bryce R, Goldstein LJ, Study G. Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study. Clinical breast cancer, 19(2):97-104.e4, 2019. PubMed
Goldstein, LJ, Gray, R, Badve, S, Childs, BH, Yoshizawa, C, Rosley, S, Shak, S, Baehner, FL, Ravdin PM, Davidson, NE, Sledge, GW, Perez, E, Shulman, LN, Martino, S, Sparano, JA: Prognostic Utility of the 21-Gene Assay in Hormone Receptor Positive Operable Breast Cancer with Classical Prognostic Factors and an Integrator of Classical Clinicopathologic and Treatment Information. JCO, Vol. 26, No. 25, Pg. 4063, September 2, 2008. PubMed
Goldstein, L.J., O’Neill, A., Sparano, J.A., Perez, E.A., Shulman, L.N., Martino, S.,Davidson, N.: Concurrent doxorubicin plus doxetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0-3 positive axillary nodes: results of North American Breast Cancer Intergroup Trial E2197. JCO, Vol. 26, No. 25, Pg. 4092, September 2, 2008. PubMed
Finn, RS, Bengala, C, Strauss, LC, Fairchild, J, Sy, O, Ibrahim, N, Rouche, H, Sparano, J, Goldstein, LJ.: Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study. Clin Cancer Res. 2011 Nov 1;17(21):6905-13.
Tevaarwerk AJ, Gray R, Schneider BP, Smith ML, Wagner LI, Fetting J, Davidson N, Goldstein LJ, Miller KD, Sparano JA. Survival in Metastatic Recurrent Breast Cancer after Adjuvant Chemotherapy: Little Evidence for Improvement Over the Past Three Decades. Cancer. 2013 Mar;119(6):1140-8. PMCID: 3593800
Goldstein, LJ, Tosello-Oliveria, C, Heinrich B, Stemmer SM, Mala C, Kastner S, Bevan P Richters L, Schmalfeldt B, Harbeck N. A Randomized double-blind phase II study of the combination of oral WX-671 plus capecitabine vs capecitabine monotherapy in first-line HER2-negative metastatic breast cancer (MBC). ASCO 2013 Oral presentation, J. Clin Oncol 31, suppl; Abstract 508.
Goldstein LJ, Gurtler J, Del Prete SA, Tjulandin S, Semiglazov VF, Bayever E, Michiels B. Trabectedin as a Single-Agent Treatment of Advanced Breast Cancer After Anthracycline and Taxane Treatment: A Multicenter, Randomized, Phase II Study Comparing 2 Administration Regimens. Clinical Breast Cancer, 14(6):396-404, 2014.
Freedman GM, Fowble BL, Li T, Hwang ES, Schechter N, Devarajan K, Anderson PR, Sigurdson ER, Goldstein LJ, Bleicher RJ.: Risk of Positive Nonsentinel Nodes in Women with 1-2 Positive Sentinel Nodes Related to Age and Molecular Subtype Approximated by Receptor Status. Breast J Vol. 20(4) 358-363, July 2014. PubMed
Adams S, Gray RJ, Demaria S, Goldstein LJ, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, Badve SS.: Prognostic Value of Tumor-Infiltrating Lymphocytes (TILs) in Triple Negative Breast Cancers (TNBC) from two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014 Sept 20; 32(27):2959-67. PMID: 25513417.
Silverman, D, Ruth, KJ, Sigurdson, E, Egleston, BL, Goldstein, LJ, Boraas, M, Bleicher R.: Skin Involvement and Breast Cancer: Are T4b Lesions of All Sizes Created Equal? Journal of the American College of Surgeons. Vol 219(3) 534-544 September 2014. PMCID: 4143438.
Matro J, Walia R, Tumelty K, Morrison T, Goldstein LJ.: Bilateral Hypoglossal Nerve Palsy Due to Breast Cancer Skull Base Metastases. AJHO Vol 10(5) 14-16, Nov. 2014.
Additional Publications
Related Articles
14 PATIENT COMMENTS
-
5.0
September 26, 2019
Dr. Lori Goldstein has a beautiful manner making me feel comfortable and confident in her care. [...]
-
5.0
August 25, 2019
Dr. Goldstein for me is a loving and kind doctor she really cares.
-
5.0
August 17, 2019
I have never met such a great doctor like Dr. Goldstein. She is so concern about your care and very compassion I feel, so fortunate to have her as my doctor. The staff members are always polite!
-
5.0
August 06, 2019
Lori & her team are outstanding!
-
5.0
August 06, 2019
I'm extremely pleased with the care that has been provided.
-
5.0
July 10, 2019
Always a good experience very pleased with my care.
-
5.0
April 30, 2019
Everybody seems to be very friendly and care and understand your problems
-
5.0
April 23, 2019
had an excellent experience with both Dr Goldstein and Dr [...]
-
5.0
April 11, 2019
Great provider and nurses! Always a good experience.
-
5.0
March 25, 2019
LOVE my Fox Chase team - Dr. Goldstein is the best.
-
5.0
March 14, 2019
I love the concern Dr. Goldstein exhibits and the entire staff are excellent.
-
5.0
February 17, 2019
Dr. Goldstein & her staff are wonderful. They took time to answer all my questions. (I) never felt rushed.
-
5.0
February 12, 2019
My provider Dr. Goldstein is the best in the country.
-
4.4
December 16, 2018
Would highly recommend Dr. Lori Goldstein as a medical oncologist to help you with breast cancer treatment. Very caring, compassionate and knowledgeable.
LOAD MORE